男性乳腺癌的研究进展-邓锋

2016122312ChinJBasesClinGeneralSurgVol23No12Dec2016•1538•830054malebreastcancerMBCMBC1/2BRCA1/2MBCsentinellymphnodebiopsySLNBMBCMBCMBCfemalebreastcancerFBCMBCMBCResearchProgressofMaleBreastCancerDENGFeng,ADILIJIANGMaimaitiming,LUANMei-xiang,DILIMULATIAisimutula.DepartmentofBreastSurgery,TheFirstAffiliatedHospitalofXinjiangMedicalUniversity,Urumqi830054,XinjiangUygurAutonomousRegion,ChinaCorrespondingAuthor:DILIMULATI·Aisimutula,E-mail:[e-mail]mmarizetheresearchprogressofthecause,treatment,andotheraspectsinmalebreastcancer(MBC).MethodsThroughreadingtherelatedliteratures,relevantliteraturesofMBCwerereviewed.ResultsFamilyhistory,BRCA1/2mutation,theimbalanceoflevelofestrogenandandrogen,andotherfactorswereriskfactorsoftheMBC.Sentinellymphnodebiopsy(SLNB)wasfeasibleintheMBC.RadiotherapycouldcontrollocalrecurrenceofMBC,andchemotherapymaybebeneficialforlong-termsurvivalrateofMBC.TheendocrinetherapyprincipleforMBCwasnotexactasfemalebreastcancer(FBC).ConclusionsMBChasmanyriskfactors.Radiotherapy,chemotherapy,andendocrinetherapyarebenefittoMBCpatients,butitstillneedstobeconfirmedbymanyhigh-qualityclinicalresearchesoflargesample.KeywordsMalebreastcancer;Riskfactors;TreatmentDOI10.7507/[e-mail]·[e-mail]0.5%1%1%MBC[1-2]MBCMBCfemalebreastcancerFBC[3][4-5]MBC59.8±9.5FBC510[6]MBC2000MBCFBC[7]MBCFBC[8]MBCMBC1MBC1.1MBC[9]15%20%MBCFBCMBC2016122312ChinJBasesClinGeneralSurgVol23No12Dec2016•1539•81317MBC1BRCA12BRCA2BRCA24%40%BRCA14%[10]BRCA2BRCA1[11]BRCA1/2MBCBRCA1/2FBCBRCA2MBCBRCA2MBCP450c17CYP172CHEK2MBC1.2MBCMBCMBC[12]MBC[13]Brinton[14]MBCMBC1.3[15]MBC2MBCMBC6070MBC[16]MBCFBCXMBC92%90%[17]MRI95%[18]2.1MBCMBCFBCMBC90%7%11%2.6%5.0%[19-20]MBCER/PR[9]Nilsson[21]MBCERPR93.0%77.0%[19]135MBCERPR83.7%77.0%[22]43MBC[20]55MBCERPRMBCERPRFBCMBCMBC15%MBC2HER-2Leone[23]1080MBCHER-2HER-22.2MBCMBCFBC[24-25]MBCMBCMBCERMBC[26]HER-2[24]3MBC3.1MBC[27]MBCsentinellymphnodebiopsySLNBMBCSLNBFBC[28]Maráz[29]SLNBMBCFBCMBCMBCSLNBaxillarylymph2016122312ChinJBasesClinGeneralSurgVol23No12Dec2016•1540•nodedissectionALNDALNDSLNBMBCSLNBMBCSLNBbreast-conservingtherapyBCTMBCSEER[30]19%MBC[31]BCTMBCMBCBCT5BCT3.2MBCFBC[32]MBCFBC5cm41355MBC[33]75MBC[34]463.3[35]FBCFBCMBCCMF+5-+FAC++MBC135MBC[36]MBC24CMF580%Sun[37]3.4MBCFBCFBC13St.Gallen[38]TAMAIs[39]MBCFBCMBCERPR[9][40]MBC[36]38MBCMBC[41]4072FBCTAMAIsGnRHHER-23.4.1TAMTAMTAMERβCTAMERPRFBCMBCER93%PR77%[21]MBC[14]2002[42]2016122312ChinJBasesClinGeneralSurgVol23No12Dec2016•1541•TAMMBCTAM561%44%556%28%TAM[43]MBCTAM51097.9%79.6%TAM72.6%42.3%[44]ARARTAMAIsTAMMBC1.5MBC[45]TAMMBC21%[46]FBC70.3%[47]MBCTAMMBC[46]3.4.2AIsAIs3AIsFBCMBCAIs50%80%GnRH1[48]ERPRFBC3AIsTAM[49]MBCAIsFBCMBCEggemann[45]MBCTAM[49]AIs15MBC2427TAM[50]AIsAIsFSHLHAIs[49][51]MBCTAMAIsKuba[52]AIsLHRHMBC3.4.3GnRHGnRHGnRH10GnRHFBCMBCFBC[53]MBCAIsGnRH[54]AIsGnRHMBCAIs3DiLauro[48]3.4.420%80%AIsMBCAR40.2%FBC[44]2040ARMBCMBC[55]ER/HER-2+42451AR+28150mg18%12ARARMBC3.4.5ERTAMER[56]TAMAIsFBC500mgZagouri[57]73.9%FBCMBC15%MBCHER-2[58]HER-2MBC2016122312ChinJBasesClinGeneralSurgVol23No12Dec2016•1542•MBCCYP17CHEK2MBCMBCFBCMBCFBCMBCMBC1RuddyKJ,WinerEP.Malebreastcancer:riskfactors,biology,diag-nosis,treatment,andsurvivorship.AnnOncol,2013,24(6):1434-1443.2LyD,FormanD,FerlayJ,etal.Aninternationalcomparisonofmaleandfemalebreastcancerincidencerates.IntJCancer,2013,132(8):1918-1926.3,,,.217077.,2016,31(4):328-332.4KordeLA,ZujewskiJA,KaminL,etal.Multidisciplinarymeetingonmalebreastcancer:summaryandresearchrecommendations.JClinOncol,2010,28(12):2114-2122.5SerarslanA,GurselB,OkumusNO,etal.Malebreastcancer:20yearsexperienceofatertiaryhospitalfromthemiddleblacksearegionofTurkey.AsianPacJCancerPrev,2015,16(15):6673-6679.6Chavez-MacgregorM,ClarkeCA,LichtensztajnD,etal.Malebreastcanceraccordingtotumorsubtypeandraceapopulation-basedstudy.Cancer,2013,119(9):1611-1617.7DawoodS.Updatesfromthe2014Sanantoniobreastcancersympo-sium.IndianJMedPaediatrOncol,2015,36(1):66-70.8JohanssonI,KillanderF,LinderholmB,etal.Molecularprofilingofmalebreastcancer—lostintranslation.IntJBiochemCellBiol,2014,53:526-535.9KordeLA,ZujewskiJA,KaminL,etal.Multidisciplinarymeetingonmalebreastcancer:summaryandresearchrecommmendations.JClinOncol,2010,28(12):2114-2122.10DeJuanI,PalancaS,DomenechA,etal.BRCA1andBRCA2muta-tionsinmaleswithfamilialbreastandovariancancersyndrome.ResultsofaSpanishmulticenterstudy.FamCancer,2015,14(4):505-513.11SilvestriV,BarrowdaleD,MulliganAM,etal.MalebreastcancerinBRCA1andBRCA2mutationcarriers:pathologydatafromtheConsortiumofInvestigatorsofModifiersofBRCA1/2.BreastCancerRes,2016,18(1):15.12BrintonLA,CookMB,McCormackV,etal.Anthropometricandhormonalriskfactorsformalebreastcancer:malebreastcancerpoolingprojectresults.JNatlCancerInst,2014,106(3):djt465.13HumphriesMP,JordanVC,SpeirsV.Obesityandmalebreastcancer:provocativeparallels.BMCMed,2015,13:134.14BrintonLA,KeyTJ,KolonelLN,etal.Prediagnosticsexsteroidhormonesinrelationtomalebreastcancerrisk.JClinOncol,2015,33(18):2041-2050.15GrundyA,HarrisSA,De